Stereotaxis Reports 2020 Full Year Financial Results

Rhea-AI Summary

Stereotaxis reported its fourth quarter and full year financial results for 2020, highlighting FDA clearance for the Genesis RMN System. Fourth quarter revenue was $6.8 million, consistent with the previous year. However, full-year revenue totaled $26.6 million, a 15% decline in recurring revenue attributed to COVID-19. Operating loss for 2020 was ($6.7) million, with a cash balance of $44 million. Despite challenges, the company expects growth through new robotic system orders and further innovation, setting a strong foundation for 2021.

Positive

• Received FDA clearance for the Genesis RMN System.
• Installed initial systems in the US and Europe.
• Starting 2021 with purchase orders for five robotic systems.
• Strong cash position with $44 million in cash.

Negative

• Recurring revenue declined 15% in 2020 due to COVID-19 impact.
• Full year operating loss was ($6.7) million.

ST. LOUIS, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2020.

“2020 was a year of significant progress despite a challenging macro environment,” said David Fischel, Chairman and CEO. “The highlight of the year was receipt of FDA clearance for the Genesis RMN System and successful installations of the first systems in the United States and Europe. We begin 2021 with purchase orders for five robotic systems reflecting the initial green shoots of a broad-based global resurgence in interest in our robotic technology.”

“Stereotaxis continues to advance a robust innovation pipeline. Our proprietary robotically-navigated magnetic ablation catheter is poised to enter formal validation studies and on track for EU commercialization and initiation of a US pivotal trial in late 2021. We have made methodical progress on a set of additional innovations and expect to be in a position to showcase them at the end of the year. We are confident in the positive impact these innovations will have on patients, physicians, providers, and on Stereotaxis’ financial and strategic foundation.”

“Our commercial and technological progress was accomplished while remaining prudent with shareholder capital. Stereotaxis starts the year in the strongest financial position of its history with $44 million in cash and a modest controlled operating loss as we invest in meaningful innovation and growth initiatives.”

2020 Fourth Quarter and Full Year Financial Results
Revenue for the fourth quarter of 2020 totaled $6.8 million, consistent with the prior year fourth quarter. Recurring revenue for the quarter was $5.9 million and system revenue was $0.7 million. Revenue for the full year 2020 totaled $26.6 million. Recurring revenue of $22.0 million for the full year 2020 declined 15% from the prior year, primarily due to the impact of the COVID-19 pandemic on procedure volumes. System revenue of $3.6 million for the full year 2020 increased from $2.1 million in the prior year reflecting the successful installation of our initial Genesis RMN Systems.

Gross margin for the fourth quarter and full year 2020 were approximately 77% and 71% of revenue, respectively. Operating expenses in the fourth quarter were $6.4 million, consistent with the $6.3 million in the prior year quarter. Operating expenses for the full year 2020 totaled $25.7 million, down from $27.6 million in the prior year. Operating loss and net loss in the fourth quarter were both ($1.2) million. For the full year 2020, operating loss was ($6.7) million and net loss was ($6.6) million. Negative free cash flow for the full year 2020 was ($3.3) million, and including funding from the payroll protection program was ($1.2) million, compared to ($4.6) million for the full year 2019.

Cash Balance and Liquidity
At December 31, 2020, Stereotaxis had cash and cash equivalents of $44.2 million.

Forward Looking Expectations
Stereotaxis anticipates robust double-digit revenue growth in 2021, with robotic system revenue of $10-$20 million. Stereotaxis’ balance sheet allows it to reach profitability without the need for additional financings.

Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, February 25, 2021, at 10:00 a.m. Eastern Time. To access the conference call, dial 1-800-430-8332 (US and Canada) or 1-929-477-0591 (International) and give the participant pass code 1129681. Participants are asked to call 5-10 minutes prior to the start time. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.

About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.Stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States, including changes in government reimbursement of procedures, dependence upon third-party vendors, timing of regulatory approvals, the impact of the recent coronavirus (COVID-19) pandemic and our response to it, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Company Contacts:                                                        
David L. Fischel
Chairman and Chief Executive Officer

Kimberly R. Peery                                                        
Chief Financial Officer

314-678-6100
investors@stereotaxis.com

STEREOTAXIS, INC.
STATEMENTS OF OPERATIONS
(Unaudited)
	Three Months Ended December 31,								Year Ended December 31,
		2020				2019				2020				2019
Revenue:
Systems	$	660,510			$	311,238			$	3,626,284			$	2,066,253
Disposables, service and accessories		5,917,716				6,335,049				22,017,631				25,850,174
Sublease		246,530				246,530				986,120				986,123
Total revenue		6,824,756				6,892,817				26,630,035				28,902,550
Cost of revenue:
Systems		461,440				688,595				3,715,416				1,411,423
Disposables, service and accessories		894,625				810,196				2,962,710				3,738,914
Sublease		246,530				246,530				986,120				986,122
Total cost of revenue		1,602,595				1,745,321				7,664,246				6,136,459
Gross margin		5,222,161				5,147,496				18,965,789				22,766,091
Operating expenses:
Research and development		2,098,161				1,615,941				8,136,914				9,021,403
Sales and marketing		2,898,472				3,066,414				11,178,325				12,733,389
General and administrative		1,402,138				1,651,881				6,364,365				5,838,158
Total operating expenses		6,398,771				6,334,236				25,679,604				27,592,950
Operating loss		(1,176,610	)			(1,186,740	)			(6,713,815	)			(4,826,859	)
Interest income (expense)		(4,240	)			102,245				67,356				235,575
Net loss	$	(1,180,850	)		$	(1,084,495	)		$	(6,646,459	)		$	(4,591,284	)
Cumulative dividend on convertible preferred stock		(340,471	)			(358,049	)			(1,369,421	)			(1,429,400	)
Net loss attributable to common stockholders	$	(1,521,321	)		$	(1,442,544	)		$	(8,015,880	)		$	(6,020,684	)
Net loss per share attributed to common stockholder:
Basic	$	(0.02	)		$	(0.02	)		$	(0.11	)		$	(0.10	)
Diluted	$	(0.02	)		$	(0.02	)		$	(0.11	)		$	(0.10	)
Weighted average number of common shares and equivalents:
Basic		74,954,091				67,937,383				72,746,268				63,051,581
Diluted		74,954,091				67,937,383				72,746,268				63,051,581

STEREOTAXIS, INC.
BALANCE SHEETS
	December 31, 2020				December 31, 2019
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	43,939,512			$	30,182,115
Compensating cash arrangement		250,620				-
Accounts receivable, net of allowance of $123,614 and $380,212 at 2020 and 2019, respectively		3,515,136				5,329,577
Inventories, net		3,295,457				1,847,530
Operating lease right-of-use assets		2,235,442				-
Prepaid expenses and other current assets		1,716,014				1,470,922
Total current assets		54,952,181				38,830,144
Property and equipment, net		195,129				250,443
Operating lease right-of-use assets		-				4,286,064
Other assets		308,515				218,103
Total assets	$	55,455,825			$	43,584,754
Liabilities and stockholders' equity
Current liabilities:
Short-term debt	$	1,185,058			$	-
Accounts payable		1,608,636				2,099,097
Accrued liabilities		3,209,235				2,721,104
Deferred revenue		5,282,770				5,092,455
Current portion of operating lease liabilities		2,287,487				2,248,189
Total current liabilities		13,573,186				12,160,845
Long-term debt		973,252				-
Long-term deferred revenue		548,915				554,258
Operating lease liabilities		-				2,089,537
Other liabilities		131,231				255,517
Total liabilities		15,226,584				15,060,157
Series A - Convertible preferred stock:
Convertible preferred stock, Series A, par value $0.001; 22,513 and 23,110 shares outstanding at 2020 and 2019, respectively		5,605,323				5,758,190
Stockholders' equity:
Convertible preferred stock, Series B, par value $0.001; 10,000,000 shares authorized, 5,610,121 shares outstanding at 2020 and 2019		5,610				5,610
Common stock, par value $0.001; 300,000,000 shares authorized, 73,694,203 and 68,529,623 shares issued at 2020 and 2019, respectively		73,694				68,530
Additional paid-in capital		522,709,846				504,211,040
Treasury stock, 4,015 shares at 2020 and 2019		(205,999	)			(205,999	)
Accumulated deficit		(487,959,233	)			(481,312,774	)
Total stockholders' equity		34,623,918				22,766,407
Total liabilities and stockholders' equity	$	55,455,825			$	43,584,754

 

FAQ

What were Stereotaxis' fourth quarter revenue results for 2020?

Stereotaxis reported fourth quarter revenue of $6.8 million, consistent with the prior year.

What was the total revenue for Stereotaxis in 2020?

The total revenue for Stereotaxis in 2020 was $26.6 million.

How did COVID-19 impact Stereotaxis' financial results?

The COVID-19 pandemic led to a 15% decline in recurring revenue for Stereotaxis in 2020.

What is the current cash position of Stereotaxis?

As of December 31, 2020, Stereotaxis had cash and cash equivalents of $44 million.

What future initiatives does Stereotaxis plan for 2021?

Stereotaxis aims to validate its robotic catheter and initiate a US pivotal trial in late 2021.